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Summary
Complement dysregulation is key in the pathogenesis of atypical Haemolyt-
ic Uraemic Syndrome (aHUS), but no clear role for complement has been
identified in Thrombotic Thrombocytopenic Purpura (TTP). We aimed to
assess complement activation and cytokine response in acute antibody-
mediated TTP. Complement C3a and C5a and cytokines (interleukin (IL)-
2, IL-4, IL-6, IL-10, tumour necrosis factor, interferon-c and IL-17a) were
measured in 20 acute TTP patients and 49 remission cases. Anti-ADAM-
TS13 immunoglobulin G (IgG) subtypes were measured in acute patients
in order to study the association with complement activation. In acute
TTP, median C3a and C5a were significantly elevated compared to remis-
sion, C3a 639 ng/ml vs. 382 ng/ml (P < 0001) and C5a 164 ng/ml vs.
929 ng/ml (P < 0001), respectively. Median IL-6 and IL-10 levels were
significantly higher in the acute vs. remission groups, IL-6: 8 pg/ml vs.
2 pg/ml (P = 0003), IL-10: 6 pg/ml vs. 2 pg/ml (P < 0001). C3a levels
correlated with both anti-ADAMTS13 IgG (rs = 0604, P = 0017) and
IL-10 (rs = 0692, P = 0006). No anti-ADAMTS13 IgG subtype was associ-
ated with higher complement activation, but patients with the highest C3a
levels had 3 or 4 IgG subtypes present. These results suggest complement
anaphylatoxin levels are higher in acute TTP cases than in remission, and
the complement response seen acutely may relate to anti-ADAMTS13 IgG
antibody and IL-10 levels.
Keywords: complement, cytokines, Thrombotic Thrombocytopenic
Purpura, ADAMTS13, T cells.
Thrombotic Thrombocytopenic Purpura (TTP) and atypical
Haemolytic Uraemic Syndrome (aHUS) are thrombotic
microangiopathies (TMAs) that share common clinical fea-
tures (microangiopathic haemolytic anaemia, thrombocytope-
nia and microvascular thrombosis), but typically have a
different pathophysiology. This is reflected by the different tar-
get organs: typically, the central nervous system and heart in
TTP, while in aHUS the kidney is primarily affected.
Key to the pathophysiology of TTP is deficiency of AD-
AMTS13 (a disintegrin and metalloproteinase with a throm-
bospondin type 1 motif, member 13) and the consequent
accumulation of Ultra Large von Willebrand Factor multi-
mers (ULVWF) in the circulation, leading to platelet aggre-
gation and formation of microthrombi. The majority of cases
are idiopathic and mediated by immunoglobulin G (IgG)
antibodies to ADAMTS13 (Furlan et al, 1998; Tsai & Lian,
1998). aHUS however, has been shown to occur as a result
of dysregulation of the complement system, a family of ser-
ine proteases playing an important role in innate and adap-
tive immunity. Mutations in genes encoding tissue-bound
and fluid phase complement regulator proteins (including
CD46, Factor H, Factor I) can be found in approximately
50–60% of patients with aHUS(Kavanagh & Goodship,
2010a,b, 2011); dysregulation of complement leads to subse-
quent over-activity of complement effector proteins, includ-
ing the anaphylatoxins (complement factors C3a and C5a).
These are potent inflammatory mediators, which target and
activate the renovascular endothelium, leading to local plate-
let aggregation and microvascular thrombosis.
Although complement dysregulation has a well-established
role in aHUS, it is uncertain whether this mechanism plays a
part in the pathophysiology of TTP. Some studies have raised
the possibility of complement over-activation in TTP.
Reduced levels of serum complement C3 have been found in
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patients with TMAs having low ADAMTS13 levels(Ruiz-
Torres et al, 2005). Another study has found increased levels
of complement anaphylatoxin C3a and terminal complement
pathway components SC5b-9 in patients with acute TTP; the
same study found the presence of anti-ADAMTS13 inhibitors
was linked to increased complement activation(Reti et al,
2012). More recently, higher complement activity has been
reported in patients dying during an acute TTP episode com-
pared to patients responding to treatment, although this
study used banked citrated plasma for analysis (Wu et al,
2013).
In this study, we aimed to investigate the possible role of
complement activation in antibody-mediated TTP, by mea-
suring levels of activated components C3a and C5a in
patients with acute TTP, patients with previous acute TTP
now in remission, and comparing these with normal con-
trols. We also determined whether complement activation
was associated with total anti-ADAMTS13 IgG level. Given
IgG antibody subtypes are known to activate different com-
plement pathways with variable efficacy, we also assessed
whether there was any association between complement acti-
vation and anti-ADAMTS13 IgG subtype. Finally, given that
antibody-mediated TTP is an autoimmune disease, we also
aimed to assess the association with T helper cells types 1, 2
and 17 (Th1, Th2 and Th17), which typically have an impor-
tant role in autoimmunity, and to relate these to comple-
ment activation.
Methods
Patients
This was a prospective study, which included 20 patients
admitted to our centre with acute TTP from June 2011 to
October 2012, in whom samples were taken preceding any
therapy. Remission samples were available for 15 of these
cases and also for a cohort of 34 patients attending follow up
clinic who had previously had an acute TTP episode. The
work was approved by national ethics committees for con-
sent of both patients and controls in this study. (MREC: 08/
H0810/54, MREC: 11/LO/1153).
Thrombotic Thrombocytopenic Purpura was diagnosed
based on the presence of thrombocytopenia, microangiopath-
ic haemolytic anaemia, a normal clotting screen and an
increase in lactate dehydrogenase (LDH) to at least one and
a half times the upper limit of normal(Scully et al, 2012).
Remission was defined as a sustained platelet count of
>150 9 109/l for two consecutive days.
All acute patients had blood taken for complement and
cytokine assays, during their initial presentation, before any
therapy such as plasma exchange (PEX) or steroids was given
and, where possible, during subsequent remission. The
remission-only group had blood taken for complement and
cytokines at a single timepoint during an outpatient hospital
visit, in conjunction with routine laboratory parameters and
samples for ADAMTS13 assays. Blood was taken from nor-
mal controls to obtain local normal ranges for complement
and cytokine assays.
For all acute TTP cases, ADAMTS13 activity, anti-ADAM-
TS13 total IgG, and anti-ADAMTS13 IgG subtypes 1–4 were
measured on admission (pre-treatment). The remission
group had ADAMTS13 activity measured only. Anti-ADAM-
TS13 IgG was only measured in remission if there was a
reduction in ADAMTS 13 activity.
Sample handling
Measurement of activated complement components (includ-
ing the anaphylatoxins C3a/C5a) requires special attention to
sample handling, given the high risk of in vitro complement
activation resulting in falsely elevated levels(Mollnes et al,
1988). Although it is known that tubes containing either
EDTA or citrate both inhibit complement activation by bind-
ing Ca2+ and Mg2+ ions (and thus are vastly superior than
serum tubes), previous data suggests EDTA is superior to
citrate for this purpose (Mollnes et al, 1988). In order to
confirm this, we measured complement C3a and C5a in a
cohort of normal controls, having taken blood into EDTA,
citrate and serum tubes for comparison.
Blood for complement analysis was taken into EDTA
tubes, separated via centrifugation (2000 g) within 4 h of
collection, and stored at 70°C prior to use. Blood for cyto-
kine assays was drawn into serum tubes; samples were then
allowed to stand for 30 mins to allow clot retraction, blood
was separated via centrifugation (2000 g), and serum aspi-
rated off and stored at 70°C prior to use.
Measurement of complement anaphylatoxins and
cytokines
Measurement of complement anaphylatoxins (C3a, C5a) and
cytokines [interleukin (IL)-2, IL-4, IL-6, IL-10, tumour necro-
sis factor (TNF), interferon-c (IFN-c), IL-17a] was performed
by a Cytometric Bead Array (CBA) method. This method has
several advantages over conventional enzyme-linked immuno-
sorbent assay (ELISA), including enabling the measurement of
multiple analytes simultaneously (thus avoiding the need to
thaw samples repeatedly), a broader dynamic range, and the
use of hundreds of capture beads per analyte in each sample
well (a minimum of 200 beads for each analyte per well) result
in each sample having a large number of replicates, thus
improving accuracy. To measure anaphylatoxins, capture
beads of known fluorescence conjugated with antibodies to
C3a and C5a were initially incubated with plasma, washed and
then incubated with phycoerythrin (PE)-conjugated antibod-
ies (BD Human Anaphylatoxin Kit; BD Biosciences, San Jose,
CA, USA). The sandwich complexes formed between the
capture beads, analyte and detection reagent were then mea-
sured using a flow cytometer (BD FACSarrayTM; BD Bioscienc-
es). Cytokines pertaining to Th1 (IFN-c, IL-2, TNF), Th2
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(IL-4, IL-6, IL-10) and Th17 (IL-17a) responses were mea-
sured using CBA methodology (BD Human Th1/Th2/Th17
kit; BD Biosciences). This employed the same method as for
anaphylatoxins (above), but only one incubation: capture
beads and PE-conjugated antibodies were incubated with
plasma in one step, prior to detection using the flow cytome-
ter. Flow cytometry data was analysed using FCAP ARRAYTM soft-
ware (Soft Flow Hungary Ltd, Pecs, Hungary), to generate
results for each analyte being measured. Local normal ranges
were obtained for both complement anaphylatoxin and cyto-
kine levels by taking blood samples from 17 healthy volunteers
(controls).
ADAMTS13, anti-ADAMTS13 total IgG and subtypes
1–4
Plasma ADAMTS13 activity was measured using a fluores-
cence resonance energy transfer (FRET) assay (Kokame et al,
2005). ADAMTS13 activity was expressed as a percentage
relative to the activity in pooled normal plasma (normal
range 60–123%; lower limit of detection <5%). Anti-ADAM-
TS13 IgG was measured using an ELISA technique, as previ-
ously described (Chow et al, 2007; Scully et al, 2007)
(normal range <61%). Anti-ADAMTS13 IgG subtypes 1–4
were also measured using an ELISA-based method. Microti-
tre plates were coated with recombinant ADAMTS13 (Baxter
Innovations GmbH, Vienna, Austria) via overnight incuba-
tion at 4°C. Plates were then blocked with 2% Bovine Serum
Albumin for 1 h. Diluted patient and standard/control sam-
ples were then added to wells and incubated for 2 h. Follow-
ing washing, monoclonal biotinylated antibodies to either
anti human IgG1, 2, 3 or 4 (Sigma-Aldrich Chemical Com-
pany Ltd, Dorset, UK) were added to wells and incubated for
90 min. Following a further wash, Streptavidin (Merck
Chemicals, Nottingham UK) was added to each well and
incubated for 30 min. A substrate buffer [Phosphate-citrate
buffer with urea hydrogen peroxide tablets (P-9305)]
(Sigma-Aldrich Chemical Company Ltd) was added and the
reaction was then stopped with 2 mol/l sulphuric acid after a
colour reaction was achieved. Plates were then read at
450 nm, and the amount of IgG subtype present was calcu-
lated by relating the optical density of the patient sample to
the optical density of a standard (expressed as a percentage).
Statistical analysis
Complement, cytokine and IgG data was not normally dis-
tributed, and therefore non-parametric methods were used
for analysis. The Mann–Whitney U test was used to compare
groups, and paired data was compared using the Wilcoxon
signed-rank test. Statistical dependence between variables was
assessed using the Spearman’s rank correlation coefficient.
P-values <005 were regarded as statistically significant. Sta-
tistical analyses were conducted using IBM SPSS Statistics for
Windows, Version 20.0 (IBM Corp., Armonk, NY, USA),
Analyse-it version 2.30 (Analyse-it Software Ltd, Leeds,
UK), and GRAPHPAD PRISM version 6.0 (GraphPad software
Inc., La Jolla, CA, USA).
Results
Patients
Over the study period, samples were obtained from a total of
20 patients (female (F) = 11, male (M) = 9) with acute TTP,
and 49 patients (F = 31, M = 18) who were in complete
remission following a prior acute TTP episode. For 15/20
acute TTP patients (F = 8, M = 7) paired samples (acute
and remission) were available. Detailed admission parameters
for acute patients, including markers of disease severity (pri-
marily LDH, Troponin T, and presence of neurological
symptoms (fall in Glasgow Coma Score below normal or any
focal neurology), are shown in Table I. Also shown are num-
ber of PEX episodes, number of rituximab infusions given
and time taken to attain remission.
All acute patients (n = 20, median age 43 years, range
17–79 years) had ADAMTS13 < 5% and the presence of
anti-ADAMTS13 IgG antibodies, with a median total IgG
level of 52% (range 5–117%). Median Hb 865 g/l (range
48–136 g/l), platelet count 11 9 109/l (range 4–130 9 109/l)
and LDH 1185 iu/l (range 346–2517 iu/l) were all in keeping
with a diagnosis of acute TTP. 18/20 patients had acute de
novo TTP, with the remaining two patients having an acute
relapse. Median Troponin T was 0025 lg/l (range 0003–
0277 lg/l). 14/20 (70%) acute patients had neurological
symptoms at presentation, and 10/20 (50%) required inten-
sive therapy unit (ITU) admission, of which one patient was
intubated. The median number of PEX episodes required to
attain remission was 175 (range 3–57) and median number
of rituximab infusions was 4 (range 1–9). The median time
to remission was 15 d (range 3–43 d).
The remission group (n = 49, median age 45 years, range
18–81 years) had a median ADAMTS13 of 82% (range
29–130%). All patients had had at least one prior acute TTP
episode, a median of 155 months (range 1–125 months)
prior to the remission sample being taken.
Complement C3a/C5a
Effect of sample type on in vitro complement activa-
tion. Complement C3a and C5a levels were measured in
seven control subjects, for whom blood was taken into EDTA,
citrate and serum tubes for comparison. For C3a, levels
obtained from serum samples were significantly higher than
EDTA (median C3a 1928 ng/ml (range 1239–3797) vs.
4273 ng/ml (range 3571–5610) respectively, P = 002); cit-
rate samples resulted in higher but non-significant levels of
C3a compared to EDTA (median C3a 5728 ng/ml (range
3113–104) vs. 4273 ng/ml (range 3571–5610) respectively,
P = 0109), Fig 1A. For C5a, serum levels were significantly
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higher than EDTA (median C5a 1472 ng/ml (range 693–
1936) vs. 7038 ng/ml (range 478–1314) respectively,
P = 002; there was no significant difference was seen between
EDTA and citrate samples for C5a, P = 008, Fig 1B.
Normal controls. Complement C3a and C5a levels were mea-
sured in 17 normal healthy controls. Median control C3a lev-
els were 437 ng/ml (range 3254–5610) and C5a levels were
581 ng/ml (range 171–136).
Complement activation in acute and remission patients. Com-
plement anaphylatoxin C3a levels in the acute TTP group
were significantly elevated compared to normal controls,
median C3a 639 ng/ml (range 271 to 1385) vs. 437 ng/ml
(range 3254 to 5610) respectively, P = 004. C5a levels were
also significantly higher than controls, median C5a 164 ng/
ml (range 494–373) vs. 581 ng/ml (range 171–136)
respectively, P < 0001. However not all patients had levels
above the upper limit of the normal range: for C3a, 12/20
(60%) were elevated above normal, with 14/20 (70%) for
C5a. Comparing the acute and remission TTP groups as a
whole, both C3a and C5a were significantly higher in the
acute TTP vs. remission group, median C3a 639 ng/ml vs.
382 ng/ml (P < 0001), and median C5a 164 ng/ml vs.
929 ng/ml (P < 0001), respectively (shown in Fig 2A, B). A
significant difference in acute and remission C3a and C5a
levels was also seen for the 15 patients with paired samples:
median C3a 506 ng/ml vs. 365 ng/ml P = 00054 and med-
ian C5a 157 ng/ml vs. 929 ng/ml P = 0018 (see Fig 2C, D
respectively). For all patients as a whole, remission C3a levels
were not significantly higher than normal controls, median
C3a 365 ng/ml vs. 437 ng/ml respectively; conversely C5a
levels in remission remained elevated, median C5a 929 ng/
ml vs. 581 ng/ml, P = 0002.
(A) (B)
(C) (D)
Fig 2. Complement C3a (A) and C5a (B) lev-
els for three groups: acute Thrombotic Throm-
bocytopenic Purpura (TTP, n = 20), remission
TTP (n = 49) and controls (n = 17). C3a and
C5a levels were significantly higher in acute
TTP vs. remission TTP (P < 0001 for both).
C3a (C) and C5a (D) levels for the 15 patients
who had paired acute and remission samples
are also shown. Levels were higher in acute
TTP vs. remission TTP; C3a P = 0005, C5a
P = 0018. The dotted line indicates the upper
limit of the normal range.
(A) (B)
Fig 1. Comparison of (A) complement C3a
and (B) C5a levels obtained from 7 normal
controls, for samples taken into EDTA, serum
and citrate tubes.
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Three patients had higher C5a levels at remission than
during the acute episode (Fig 2D); none of these were
remarkable in terms of time taken to attain remission or
treatment required (number of PEX episodes or rituximab
infusions). Furthermore, none of these patients had either a
milder clinical course at presentation or any increased risk of
relapse following treatment. The two highest C3a and C5a
levels seen during acute episodes were seen in four individual
patients (Fig 2C, D respectively). Although the two patients
having the highest C3a levels required more rituximab doses
than the standard number of four infusions (six and eight
infusions), there was no significant association demonstrated
between C3a or C5a levels and number of PEX required,
number of rituximab required or time taken to attain remis-
sion.
Cytokines
Of the cytokines assayed, only IL-6 and IL-10 were significantly
elevated in the acute TTP group compared to the remission
group: median IL-6: 9785 pg/ml vs. 2405 pg/ml
(P = 00013), IL-10: 6375 pg/ml vs. 18 pg/ml (P < 0001)
respectively (Fig 3A, B). Despite levels of these two cytokines
in acute TTP being higher than remission, only seven acute
cases had IL-6 levels above the upper limit of normal
(>992 pg/ml) and five cases had IL-10 levels above normal
(>716 pg/ml). There was no significant difference in acute vs.
remission cytokine levels within the group having paired acute
and remission samples. A positive correlation was present
between IL-10 level and C3a level, rs = 0692 (P = 0006), and
IL-10 level and LDH, rs = 0703 (P = 0007).
Complement, anti-ADAMTS13 IgG and
anti-ADAMTS13 IgG subtype
For all acute patients a positive correlation was seen between
C3a level and anti-ADAMTS13 IgG antibody level, rs=0604
(P = 0017) (Fig 4A). Anti-ADAMTS13 IgG was also posi-
tively correlated with LDH r = 0502, (P = 0028). The anti-
ADAMTS13 IgG subtype levels for acute patients are shown
in Fig 4B. The highest median subtype level (as a % relative
to a standard) was seen with IgG2. There was no correlation
between either C3a or C5a levels and any particular IgG sub-
type. However, when patients were categorized according to
number of IgG subtypes (1–4) present, the highest C3a levels
were seen with those patients having three or more IgG
subtypes.
Complement and markers of disease severity
C3a and C5a levels were compared in patients with acute TTP
having presence or absence of the following markers of disease
severity: ITU admission, neurological symptoms and elevated
Troponin T (>004 lg/ml). No significant difference was
shown for either C3a or C5a for any of the three markers.
Discussion
We have presented the largest prospective study to date that
describes changes in complement activation markers and
cytokines in acute and remission TTP cases. Complement
activation occurring acutely was demonstrated by a between-
group comparison of 20 acute and 49 remission TTP cases,
and a within-group comparison of 15 patients with paired
acute and remission samples. Elevation in C3a and C5a was
seen in acute cases, for both the between-group and within-
group comparison, and acute levels were significantly higher
than in remission. However, there was a wide variation in
levels of C3a and C5a acutely, and not all cases had levels
above the upper limit of normal. We also quantified anti-
ADAMTS13 IgG levels for all acute cases, and were able to
demonstrate a positive correlation between anti-ADAMTS13
IgG level and C3a level. Furthermore we looked at the rela-
tionship between anti-ADAMTS13 IgG subtype and comple-
ment activation: although no individual subtype was
correlated with C3a/C5a, higher C3a levels were seen in
patients having three or more subtypes present. Finally, we
were also able to assess the Th1/Th2/Th17 cytokine response
in acute TTP, demonstrating a higher level of IL-6 and IL-10
in acute vs. remission cases.
We confirmed the importance of using EDTA plasma for
complement assays, given reduction in in vitro activation
compared with serum; results between EDTA and citrate
were comparable, but EDTA appeared to have lower C3a lev-
(A) (B)
Fig 3. Levels of (A) interleukin-6 (IL-6) and
(B) interleukin-10 (IL-10) for acute Thrombot-
ic Thrombocytopenic Purpura (TTP) and
remission TTP groups. For both IL-6 and
IL-10, levels in acute TTP were higher than in
remission, P = 0001 & P < 0001 respectively.
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els and a narrower range for controls than citrate. This find-
ing, combined with data indicating that EDTA shows better
complement inhibition over time than citrate (Mollnes et al,
1988), leads us to conclude that EDTA plasma is superior to
citrate and serum for this purpose.
The finding of complement activation in acute TTP is
interesting and raises questions regarding its role in this set-
ting. Complement can be activated directly in several ways,
including via immune complexes, or infected or damaged
cells. These activate different complement pathways, with
immune complexes typically activating the classical pathway
(Ricklin & Lambris, 2013). Therefore one potential mecha-
nism for complement activation in TTP relates to anti-AD-
AMTS13 antibodies. Antigen-antibody complexes formed
between ADAMTS13 and anti-ADAMTS13 IgG antibodies
may directly activate the classical complement pathway, lead-
ing to downstream activation of C3 and formation of C3a.
Our finding of a positive correlation between anti-ADAM-
TS13 IgG antibody level and C3a level would support this as
a potential mechanism. Our results are consistent with those
from a previous study that investigated complement activa-
tion markers in TTP (Reti et al, 2012), which found higher
C3a levels in 13 patients with acute TTP vs. 11 remission
cases. Our study comprised higher numbers of individual
acute and remission patients, with the vast majority of acute
cases (18/20) being de novo, compared with 8/13 reported by
Reti et al (2012).
Immune complexes are also able to activate the other
complement pathways (lectin and alternative), with particular
antibody types and subtypes being more effective than others
at activating a particular pathway. IgG subtypes 1 and 3 are
particularly effective at activating the classical pathway, with
IgG2 being better at activating the alternative pathway(Luci-
sano Valim & Lachmann, 1991). Our finding of IgG2 having
the highest median level of all the four subtypes, may suggest
that immune complexes in TTP could be activating the alter-
native as well as the classical complement pathway. Indeed
markers of classical (C4d) and alternative (C3bBbP) pathway
have both been shown to be elevated in acute TTP cases;
both correlated with downstream effector components C3a
and SC5b-9(Reti et al, 2012).
Aside from immune complex-mediated complement acti-
vation, there are other potential ways in which complement
might be activated in TTP. Part of the role of complement
relates to recognizing and clearing damaged cells; given the
organ damage occurring in TTP secondary to microvascular
thrombosis, this alone may be sufficient to activate the alter-
native complement pathway. Over-activation of the alterna-
tive pathway has also been found to be implicated in a
variety of autoimmune diseases (Klos et al, 2009), including
systemic lupus erythematosus (Alegretti et al, 2012; Elkon &
Santer, 2012). Indeed it is the alternative pathway that has
been found to be overactive as a result of defective comple-
ment regulation in aHUS(Kavanagh & Goodship, 2010a,b,
2011). The finding of significant elevation of IL-6 and IL-10
in acute cases compared to remission, may indicate a
possible mechanism driving the immune response in anti-
body-mediated TTP. Although IL-10 is an anti-inflammatory
cytokine, it has an important role in enhancing B-cell sur-
vival, proliferation and antibody production (Iyer & Cheng,
2012); as such it is possible that IL-10 may stimulate anti-
ADAMTS13 IgG production, and lead to antibody-mediated
complement activation. The finding of a positive correlation
between IL-10 and anti-ADAMTS13 IgG may support this
hypothesis, as well as the fact that both IgG and LDH are
positively correlated with LDH, a marker of disease severity
in TTP. High IL-6 levels may relate to the inflammatory
response associated with microvascular thrombosis in TTP
(Gabay, 2006; Mihara et al, 2012).
The variations in degree of complement activation in acute
TTP are notable, and there are various possibilities for this:
given the positive correlation between IgG level and C3a, varia-
tions in complement activation may relate to antibody burden
or potency of antibodies. Although we were not able to dem-
onstrate an association between a particular IgG subtype and
complement activation, the finding that patients with highest
C3a levels generally have three or four IgG subtypes present, is
consistent with IgG antibody burden playing a role in the
degree of complement activation occurring. Furthermore, it is
known that some IgG subtypes (in the form of immune com-
plexes) are able to activate complement better than others.
There is also evidence suggesting that the proportion of anti-
body to antigen, as well as epitope density can all affect how
strongly immune complexes activate complement(Lucisano
Valim & Lachmann, 1991). Variations in complement regula-
tion between patients may also affect the degree of activation
(A) (B)
Fig 4. (A) A positive correlation was found
between anti-ADAMTS13 IgG level and C3a.
(B) Analysis of anti-ADAMTS13 IgG subtypes–
IgG2 was found to be the subtype with the
highest median level when measured as a %
relative to a standard.
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resulting from an initial trigger. This effect may be propagated
by cytokines, such as IL-10. Serum from patients with TMAs
has been shown to trigger complement C3 and membrane
attack complex binding, when incubated with endothelial cells;
this indicates the potential for complement to activate
endothelial cells, a key process in the development of TMAs
(Ruiz-Torres et al, 2005). There is at present no direct evi-
dence that complement activation in TTP is associated with a
worse prognosis. We found no association between degree of
complement activation (C3a and C5a levels) and markers of
TTP disease severity including Troponin T, presence of neuro-
logical symptoms and ITU admission.
Elucidating the role of complement in TTP is important,
given the potential role for complement inhibition, which
has been used very successfully in disorders where defective
complement regulation is key, including Paroxysmal Noc-
turnal Haemoglobinuria (Kelly et al, 2011; Hillmen et al,
2013) and aHUS (Taylor et al, 2010; Wong et al, 2013). In
this study we have shown that complement activation is
seen in many patients with acute TTP, but further work is
needed to establish whether complement has an important
role in the pathophysiology of TTP, or if complement
activation occurs purely as a bystander mechanism in this
disease.
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